Cancel

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ...
i3 Health

Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood

Target Audience The intended audience for this activity are neurologists, neuromuscular specialists, pediatric neurologists, genetic counselors, and pediatricians. Program Overview Join a panel of expert clinicians to identify the subtle and very early signs of DMD that may be detected before functional symptoms are noticed and that can help earlier diagnoses and appropriate interventions. Panelists will review the importance of matching mutations to therapeutic decisions, discuss emergin...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with Parent Project Muscular Dystrophy (PPMD) and the National Organization for Rare Disorders (NORD).

Gastroenterology 2024 - LIVE STREAMING

The Comprehensive 2024 Gastroenterology Update This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians. Practical, Results-Driven Education Highlights of the 2024 program include: • Updated...
Harvard Medical School

Intensive Review of Nephrology - LIVE STREAMING

With over 70 interactive lectures, case discussions, board preparation sessions, and supplementary lectures, this CME program provides a comprehensive review of state-of-the-art nephrology practices offered by the clinical faculty of Harvard Medical School. It offers accelerated learning for: - Clinicians seeking a practical and comprehensive review that ensures they are up to date across all major areas of nephrology: • The latest options for diagnosis: what to choose, when, and wh...
Harvard Medical School

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ...
ACHL

Neurological Emergencies - LIVE STREAMING

Evaluation. Detection. Diagnosis. Management. In Emergency, Outpatient, and Inpatient Settings Neurological Emergencies will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies. OVERVIEW This special program provides new strategies, updates, best practices, and practical tips for: • The WORKUP of common neurological complaints and high-risk conditions • RAPID DETECTION of a neurological emergency and EARLY ACTIONS to opt...
Harvard Medical School

Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment

There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the tre...
Integritas Communications

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map